Free Trial

Biodexa Pharmaceuticals (BDRX) News Today

→ Democrats’ “break glass for emergency” candidate for 2024 (From The Freeport Society) (Ad)
Free BDRX Stock Alerts
$0.98
-0.02 (-1.99%)
(As of 09:04 AM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestTrends
June 13 at 9:35 AM | globenewswire.com
Results of Annual General Meeting
June 10, 2024 | globenewswire.com
Twelve month Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis (FAP) to be Presented at Prestigious Biennial InSIGHT 2024 Meeting in Barcelona
May 22, 2024 | msn.com
Biodexa Pharmaceuticals Stock Is Tumbling Wednesday: What's Going On?
May 22, 2024 | msn.com
Gold Moves Lower; Macy's Boosts 2024 Forecast
May 22, 2024 | globenewswire.com
Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises
May 21, 2024 | finance.yahoo.com
Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa’s Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting
May 21, 2024 | globenewswire.com
Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa's Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting
May 21, 2024 | investorplace.com
Why Is Biodexa Pharmaceuticals (BDRX) Stock Up 78% Today?
May 15, 2024 | finance.yahoo.com
Posting of Annual Report & Notice of AGM - Total Voting Rights
April 30, 2024 | finance.yahoo.com
Biodexa’s Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting
April 30, 2024 | globenewswire.com
Biodexa's Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting
April 26, 2024 | investorplace.com
Why Is Biodexa (BDRX) Up 70% Today?
April 26, 2024 | marketbeat.com
Trading was temporarily halted for "BDRX" at 09:04 AM with a stated reason of "LULD pause." Trading set to resume at 09:04 AM.
April 26, 2024 | finance.yahoo.com
Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)
April 26, 2024 | globenewswire.com
Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)
April 19, 2024 | globenewswire.com
Preliminary Results for the Year Ended 31 December 2023
April 3, 2024 | msn.com
7 stocks to watch on Tuesday: CHX on SLB deal, managed care players and more
April 3, 2024 | msn.com
View reaches deal with Cantor Fitzgerald and RXR to become a private company
April 2, 2024 | seekingalpha.com
Job openings roughly flat in February, with prior month's print revised down - JOLTS
April 2, 2024 | msn.com
U.S. factory orders rise more than forecast in February
March 30, 2024 | uk.investing.com
Biodexa reports promising brain cancer drug results
March 28, 2024 | finanznachrichten.de
Biodexa Pharmaceuticals Plc: Biodexa's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers
March 28, 2024 | benzinga.com
Gold Gains 1%; Walgreens Narrows Earnings Forecast
March 28, 2024 | msn.com
US Stocks Flat; Initial Jobless Claims Fall To 210,000
March 18, 2024 | msn.com
Biodexa Pharmaceuticals files to sell 1.28B shares for holders
March 1, 2024 | msn.com
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading But End Week Flat
February 23, 2024 | finanznachrichten.de
Biodexa Pharmaceuticals PLC: Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update
February 23, 2024 | globenewswire.com
Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update
February 9, 2024 | finanznachrichten.de
Biodexa Pharmaceuticals PLC: Biodexa Reports 12 Month Survival in MAGIC-G1 Study of MTX110 in Recurrent Glioblastoma Patients
January 22, 2024 | finanznachrichten.de
Biodexa Pharmaceuticals PLC: Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024
January 22, 2024 | finance.yahoo.com
Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024
December 25, 2023 | uk.finance.yahoo.com
Biodexa Pharmaceuticals Plc (BDRX)
December 21, 2023 | finance.yahoo.com
Biodexa Announces Closing Of $6.0 Million Underwritten Public Offering, Including Full Exercise Of Overallotment Option
December 19, 2023 | msn.com
Why Biodexa Pharmaceuticals (BDRX) Shares Are Getting Hammered
December 11, 2023 | msn.com
European Equities Traded in the US as American Depositary Receipts Open Week Slightly Higher in Monday Trading
November 30, 2023 | msn.com
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading
November 29, 2023 | msn.com
European Equities Traded in the US as American Depositary Receipts Trend Slightly Higher Wednesday
November 28, 2023 | marketbeat.com
Trading was temporarily halted for "BDRX" at 03:11 PM with a stated reason of "LULD pause."
November 27, 2023 | marketbeat.com
Trading was temporarily halted for "BDRX" at 10:11 AM with a stated reason of "LULD pause."
November 27, 2023 | marketbeat.com
Trading was temporarily halted for "BDRX" at 09:11 AM with a stated reason of "LULD pause."
November 27, 2023 | marketbeat.com
Trading was temporarily halted for "BDRX" at 09:11 AM with a stated reason of "LULD pause."
November 27, 2023 | finance.yahoo.com
Biodexa Enters Into Agreements to Acquire Exclusive Worldwide License to Tolimidone, a Phase II Ready Asset for Type 1 Diabetes
November 27, 2023 | marketbeat.com
Trading was temporarily halted for "BDRX" at 09:11 AM with a stated reason of "LULD pause."
October 3, 2023 | finanznachrichten.de
Biodexa Pharmaceuticals PLC: Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent Glioblastoma
September 21, 2023 | finance.yahoo.com
Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at 2023 Annual European Association of Neuro-Oncology Meeting (EANO)
August 31, 2023 | marketbeat.com
Trading was temporarily halted for "BDRX" at 02:08 PM with a stated reason of "LULD pause." Trading set to resume at 02:08 PM.
August 31, 2023 | marketbeat.com
Trading was temporarily halted for "BDRX" at 02:08 PM with a stated reason of "LULD pause." Trading set to resume at 02:08 PM.
August 31, 2023 | marketbeat.com
Trading was temporarily halted for "BDRX" at 02:08 PM with a stated reason of "LULD pause." Trading set to resume at 02:08 PM.
August 31, 2023 | marketbeat.com
Trading was temporarily halted for "BDRX" at 02:08 PM with a stated reason of "LULD pause."
August 15, 2023 | msn.com
European Equities Traded in the US as American Depositary Receipts Move Lower in Tuesday's Session
Get Biodexa Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for BDRX and its competitors with MarketBeat's FREE daily newsletter.

Top-Secret Government Project Revealed (Ad)

Details a top-secret program for taking America’s most critical technology mainstream. And it has nothing to do with artificial intelligence, cryptocurrency, or the blockchain.

To get all the details of this new tech – click here now.

BDRX Media Mentions By Week

BDRX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

BDRX
News Sentiment
▼
0.63

0.88
▲
Average
Medical
News Sentiment

BDRX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

BDRX Articles
This Week
▼
3

1
▲
BDRX Articles
Average Week

Get Biodexa Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for BDRX and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:BDRX) was last updated on 6/14/2024 by MarketBeat.com Staff

From Our Partners
Gold Prices Surge and This $0.32 Stock Is Reaping The Rewards
Gold prices are on the rise. This surge in gold prices is great news for gold mining stocks. Especially ...
Market JAR | Sponsored
AI's Next Magnificent Seven
The Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.
The Oxford Club | Sponsored
Executive Order To Wipe Out Your Bank Accounts
Don't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...
Oasis Gold | Sponsored
Biden to Launch “FedNOW” [Move Your Money Now]
Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...
Priority Gold | Sponsored
Jeff Bezos & 48 Members of Congress Are Buying ONE Sector…
Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...
InvestorPlace | Sponsored
Biden’s Tax Plan Could Destroy Your Retirement Savings!
Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...
GoldenCrest Metals | Sponsored
The Single Biggest Breakthrough of the Decade
Billionaires, Jeff Bezos, Bill Gates, Warren Buffett, and Sir Richard Branson are rallying behind this technol...
Porter & Company | Sponsored
Estee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI company
A Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.
Financial Markets Daily | Sponsored